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This study helps to fill a remaining knowledge gap surrounding the mechanisms and
pathways that contribute to cardiomyopathies in SCD. A better understanding of the
pathophysiological mechanisms could lead to more accurate therapeutic targets to improve
quality of life as well as life expectancy. In this study I recapitulate cardiac dysfunction in vitro
by exposing engineered mouse cardiac tissues to ANG II or the sickled microenvironment.
Experimental results include gene expression profiles and oxidative stress generation.
Gene expression profiles in the ANG II treated tissues indicated a pathological state with
upregulation in biomarkers for inflammation, cell adhesion, wall stress and ECM related genes.
Further research is being conducted using insights gained from this study which will lead to a
broader understanding of the biological processes involved and potentially identify novel
therapeutic targets that may ultimately improve patient outcomes.
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CHAPTER I
INTRODUCTION: SICKLE CELL DISEASE
1.1

Motivation
Sickle cell disease (SCD) is an inherited genetic disorder that is caused by a mutation in

the -globin gene leading to pathophysiological consequences. In 1910, Dr. James Herrick
reported the first recognition of SCD, through his description of irregularly shaped red blood
cells as a “large number of thin, elongated sickle-shaped and crescent-shaped forms” [1]
Unfortunately, due to high infant mortality rates and vulnerability to infectious diseases, the
disease was rarely diagnosed for several decades. Nearly 50 years after Herrick’s report, Pauling
and Itano, established SCD as a molecular disease [2]. During the 1960’s the disease became a
political symbol for equal rights of black Americans. In response to the increased social
awareness, comprehensive SCD centers were established in the USA during the 1970’s.
Subsequently by 1994, the median age of death rose from less than 20 years or age to 48 and 42
years of age, in women and men, respectfully. Through advances in comprehensive care and the
introduction of hydroxyurea, survival to 18 years of age reached 96% in 2010 [3]–[7]. Despite
the improved survival for children and adolescents, adult SCD-related mortality may have
increased. The centers for disease control and prevention’s (CDC) sickle cell data collection
(SCDC) program found the most frequent and severe symptoms occurred during the transition
from pediatric to adult care. A recent study reported patients 20-25 years of age exhibit two
times the mortality than patients 15-19 years of age. SCD continues to be associated with poor
1

outcomes with major consequences of cardiac morbidity, early mortality, and sudden death.
Through a better understanding of the pathophysiology of SCD, more accurate therapeutic
targets can be distinguished to improve not only life expectancy, but also the quality of life.
Through the use of a physiologically relevant in vitro platform, this study will help to fill
remaining knowledge gaps surrounding the mechanisms and pathways that contribute to
cardiomyopathies in conjunction with SCD.
1.2
1.2.1

Genetics
Hemoglobin
Hemoglobin is a vital protein found in most vertebrates as well as some invertebrates. It

is the main protein in mature red blood cells (RBC) and functions as the oxygen carrying
component. Hemoglobin is a tetramer composed of four globin subunits. Each globin subunit is
associated with a heme thus allowing a molecule of oxygen to bind to each subunit
[8].Consequently, hemoglobin has an increased oxygen-transport from the lungs to the remainder
of the body for cellular respiration [8]. There are at least six genes that encode various types of
globin subunits thus generating variations of the hemoglobin tetramer.
Fetal hemoglobin (HbF) is the heterodimeric combination of two alpha-globin and two
gamma-globin proteins [9]. HbF is the predominant hemoglobin type after the first trimester of
gestation and is gradually replaced by adult hemoglobin shortly after birth [10]. From birth
through the first several months of life, the presence of high levels of HbF protect against vasooccclusive events and hemolytic features of SCD [11]. In adults, HbF generally compromises
less than 1% of total hemoglobin [12].
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Newborns undergo a transition from fetal hemoglobin (HbF) to adult hemoglobin (HbA).
HbA is the preeminent expression of hemoglobin in healthy adults. This molecule is composed
of two alpha-globin subunits and two beta-globin subunits [13].
Hemoglobin A2 (HbA2 ) is less common HbA accounting for approximately 3% in
healthy adults. There is no known physiological relevance of HbA2 however, elevated levels
have been associated with individuals with sickle cell disease and other hematologic disorders
[14].
Sickled hemoglobin (HbS) is the result of a single nucleotide substitution in the HBB
gene that encodes for HbA beta-globin subunits. When a hemoglobin protein contains this point
mutation it is considered to be hemoglobin S [2], [7], [15]. Each parent contributes one copy of
the HBB gene, thus everyone recieves two copies of the HBB gene. The most severe form of
sickle cell disease (SCD), sickle cell anemia (SCA), occurs when an individual is homozygous
for HbS, meaning they have inherited HbS from each parent. Variations in SCD are the result of
a combination of a single HbS gene and other abnormal hemoglobin genes. The different types
of SCD include hemoglobin SC, SD, SE and S

thalassemia. These variations are normally less

severe and uncommon than SCA. Heterozygous individuals, expressing one normal and one
abnormal gene are considered to carry the sickle cell trait (SCT). These individuals produce HbA
and HbS as the oxygen bearing molecules in their RBCs. Typically, SCT individuals are
considered asymptomatic, however SCT has been associated with other cardiovascular
complications, morbidities, and mortalities. Additional research needs to be conducted to
elucidate the extent [4], [16], [17].

3

1.3

Pathophysiology
The pathophysiology of sickle cell disease (SCD) is predicated on the polymerization of

HbS as a result of low-oxygen tension. Hemoglobin polymerization affects the structure,
physical and biochemical properties of red blood cells (RBCs), including increased adhesion,
stiffness, morphology, and oxidative damage. Compared to HbA, HbS has reduced oxygen
affinity [18]. This reduced oxygen affinity exhibited in HbS exacerbates HbS polymerization
which in turn creates a positive feedback look further reducing the oxygen affinity of HbS. Upon
polymerization the structure of the RBCs physically deforms from the typical biconcave shape
into a sickled shape. This deformation leads to increased stiffness and impaired rheology of
RBC. Repeated cycles of polymerization and sickling in low oxygen conditions eventually
results in permanent damage to the RBC leaving the cell in an irreversible sickled state.
The increased adhesion seen in RBCs containing HbS causes the cells to adhere to the
post-capillary venule thus narrowing the lumen diameter. The blood flow velocity is inversely
proportional to the diameter of the blood vessel lumen. This combined with the increased
stiffness of sickled RBCs further impairs blood flow rheology and eventually leads to the
formation of vaso-occlusion.
Not only do HbS polymerization and vaso-occlusion play- crucial roles in the
development of the pathophysiology of SCD, they are also responsible for precipitating a
cascade of subsequent pathologic events and complications including endothelial dysfunction,
depletion of nitric oxide (NO) bioavailability, and oxidative stress. The direct contact between
the sickled RBCs and endothelial cells (EC) leads to endothelial activation and dysfunction.
Endothelial cells line the inner surface of lymphatic and blood vessels and perform important
functions in regard to the development and maintenance of vascular tone, nutrient exchange,
4

organ development, and blood fluidity. The abnormal RBC to EC interaction leads to
dysfunction of the vascular endothelium that contributes to the overall vascular pathophysiology
of SCD, specifically vaso-occlusions and chronic organ damage [19]–[21]. The endothelial
dysfunction observed in SCD can be characterized by a change in the processes of the
endothelium to a state of reduced vasodilatory responses, a proinflammatory state and
prothrombic properties. upregulation of adhesion molecules. The mechanisms involved in this
change include reduced nitric oxide production, increased oxidative stress, as well as
upregulation of adhesion molecules such as vascular cell adhesion molecule 1 (VCAM-1) and
intercellular adhesion molecule 1 (ICAM-1) as well as inflammatory mediators like interleukin 6
(IL-6).
Nitric oxide is an important regulator of vascular homeostasis and vasodilation. In SCD
there is a depletion of NO bioavailability. This is largely contributed to the1000-fold increase in
plasma hemoglobin released from hemolyzed RBC scavenging NO as compared to cytoplasmic
hemoglobin [22]. Reduced NO bioactivity can impair the regulation of blood flow and promote
RBC adhesion thereby contributing to the occlusive process. Reactive oxygen species (ROS)
scavenge NO further reducing NO bioavailability.
It is believed that the leading source of free radical production in SCD is a result of the
reoxygenation phase of RBC. During reoxygenation, RBCs generate superoxide as a byproduct
of reaction between heme iron and oxygen. In contrast to HbA, HbS becomes overwhelmed by
the perpetual source of superoxide and hydrogen peroxide. Compared to HbA, sickled cells
develop approximately twofold greater quantities of superoxide, hydrogen peroxide and
hydroxyl radicals. When hydrogen peroxide is exposed to methemoglobin, it decomposes
hemoglobin and releases iron. The iron released then reacts with residual hydrogen peroxide to
5

produce additional hydroxyl radicals. When ROS are not neutralized through ROS defense
mechanisms such as, enzymatic antioxidants, like NO, or through nonenzymatic antioxidants
such as reduced glutathione (GSH), the oxidative stress can result in increased endothelial cell
adhesion and cell destruction [18]. Furthermore, the oxidative stress oxidizes the intracellular
enzyme target of NO, soluble guanylate cyclase (sGC), rendering it inactive. In its active state,
sGC catalyzes the synthesis of cyclic guanosine monophosphate, which in turn promotes
vasodilation and inhibits smooth muscle proliferation [20]. Thus by disrupting the NO-sGC
signaling mechanism, oxidative stress leads to vascular dysfunction [23].

1.4

Clinical Manifestations
Sickle cell disease manifest in a variety of symptoms including, but not limited to pain,

anemia, infection, myocardial infarction and fibrosis. The most common clinical manifestation of
SCD is referred to as pain crisis or vaso-occlusive crisis (VOC). These painful crises are a result
of vascular sickling and hemolysis. Painful crises are often precipitated by a variety of factors
including infection, cold weather and dehydration. Patients with SCD have increased
susceptibility to infection due to their impaired immunity. The impaired immunity is partially
due to autosplenectomy.
The spleen plays an important function in immune defense and quality control of altered
RBCs. In SCD the first organ injured is typically the spleen due to recurring vaso-occlusive
infarctions in the spleen that leads to fibrosis and autosplenectomy [24]. Consequently, there is
an increased susceptibility to infection. Infection is one of the major complications of sickle cell
disease and is associated with morbidities and mortalities [13], [25]. In children, infection is the
leading cause of premature deaths [26], [27]. Malaria, pneumococcal and haemophilus infections
6

are all believed to contribute to the increased morbidity and mortality.
Cardiopulmonary complications are the major complications in individuals surviving to
adulthood with SCD. Patients with SCD have a unique cardiac pathophysiology characterized by
a restrictive physiology that is superimposed on features of hyperdynamic circulation. In SCD,
the primary characteristics of the restrictive cardiomyopathies are diastolic dysfunction, left atrial
(LA) dilation, and left ventricular (LV) enlargement [20], [27], [28]. In addition, myocardial
tissue specimens displayed an increased heart weight, myocardial fibrosis and pulmonary
vascular changes. Figures 1.1 and 1.2 compare the progression of fibrosis and heart to body mass
ratio in healthy and diseased mice using the Townes mouse model. In the Townes mouse model,
genes are knocked-in replacing endogenous mouse ɑ-globin genes with human α-globin genes
and endogenous mouse β globin genes with human Aγ and βs globin genes [29]. It is believed
that LV diastolic dysfunction is primarily associated with increased aortic stiffness while
myocardial fibrosis is correlated with increased blood transfusion requirements [30].

7

Figure 1.1

Masson’s Trichrome Stained Townes Mice Hearts

Progression of fibrosis seen in genetically modified Townes mice. Mice were bred and
phenotyped for control (HbAA), sickle trait (HbAS), and sickle cell anemia (HbSS) human
hemoglobins Scale bar = 100 m
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Figure 1.2

Heart to Body Ratio of Townes Mice

Heart to body ratio from 4-36 weeks of Townes mice bred and phenotyped for control (HbAA),
sickle trait (HbAS), and sickle cell anemia (HbSS) human hemoglobins. N = 42

Outside of painful crises, acute chest syndrome (ACS) is the most frequent reason for
hospitalization and is the leading cause of death in individuals with SCD. Over 10% of adult
cases of ACS are fatal or complicated by multi-organ failure and neurological events [13]. The
initial pulmonary injury is caused by a number of factors including infection, pulmonary
infarction, sickle cells blocking blood vessels, surgical procedures and pulmonary embolism
[28]. At the pulmonary endothelial cell level, the imbalance of NO to adhesive forces leads to
increase intrapulmonary sickle cell adhesion.

9

1.5

Clinical Treatment
Sickle cell disease is treated in a variety of ways based on the severity and symptoms

present. The most common cause of hospitalization is a result of severe pain from the condition.
Discussed below are the most relevant and promising therapies related to SCD.
1.5.1

Pain Management
Pain is considered to be one of the major consequences of SCD. Patients can begin to

suffer pain as early as infancy with increased severity throughout life. The combination of acute
pain as well as chronic pain can result in poor quality of life and hospitalization. There are two
main approaches to treat pain related to SCD. These strategies include analgesics that target the
central nervous system (CNS) and implementing disease-modifying therapies to treat the sickle
pathobiology and underlying pain [31], [32]. Currently, opioids are the most common treatments
for moderate to severe pain in SCD. Unfortunately, long term use can lead to adverse side
effects. Opioids negatively alter RBC deformability, rheology, membrane structure and
dehydration. In addition, the binding of analgesic opioids such as morphine, fentanyl and
hydromorphone, to µ-opioid receptors activates several signaling pathways that can amplify
complications. These complications include but are not limited to endothelial activity, vascular
permeability, stroke, hyperalgesia, opioid tolerance, renal pathology and retinopathy. A study
conducted using the Berkley sickled mice model investigated the influence of chronic morphine
use and demonstrated notable renal pathology and impaired renal function [33].
Due to the severity of the side effects that can arise from chronic opioid use, alternatives
pain management therapies are being investigated. Cannabis offers a novel approach for the
treatment of pain and possible hyperalgesia. Cannabis has already proven an effective alternative
10

in treating pain associated with HIV, multiple sclerosis and cancer. The BERK sickle mice model
has been used to investigate the effects of systemic administration of cannabis in SCD.
Administration of cannabis attenuated deep tissue hyperalgesia in sickle cell mice [33]. Currently
33 states and Washington D.C. have medical marijuana laws. At least 5 of these states have
approved SCD as a qualifying condition. Subsequently, retrospective studies have been
completed using the results of urine drug screen tests in adults with SCD. The results found no
significant difference in the amounts of opioids consumed between cannabis users versus
nonusers [34]. Additional human trials will need to be completed to clarify the effect and role of
cannabis for SCD treatment. Alternatively, some individuals have also found relief through the
use of nonpharmacological interventions such as massage, acupuncture, and self-relaxation
techniques [34]. In addition, physicians and caregivers recommend preventative measures and
therapies to avoid crisis triggers.

1.5.2
1.5.2.1

Approved Drug Therapies
Hydroxyurea
Hydroxyurea (HU) or hydroxycarbamide, is a ribonucleotide reductase inhibitor first

approved for use by the Food and Drug Administration (FDA) in 1998 and by the European
Medicines Agency (EMA) in 2007 for treatment of SCD. Through a mechanism that is not fully
understood, HU increases cGMP levels thereby increasing the expression of HbF and decreasing
leukocyte count [13]. The increased expression of HbF in turn reduces the concentration of HbS
in RBCs [35]. As a result of the increased HbF concentration within their RBCs, individuals
experience milder disease symptoms such as milder anemia as well as a reduction in the
frequency and severity of VOCs [35], [36]. Furthermore, HU may function as an anti11

inflammatory due to the generation of nitric oxide. Unfortunately, HU is associated with a
variety of side effects and concerns have been raised concerning toxicity and the long-term
effects. Thus there continues to be a need for the identification and development of therapeutics
to be used in conjunction with or in place of HU [37]–[40].

1.5.2.2

Glutamine
Glutamine is an influential amino acid involved in the synthesis and production of

arginine, nicotinamide adenine dinucleotide (NAD), and glutathione (GSH). These substances
are used to combat oxidative damage [20]. In SCD there is an increase in free radicals and
oxidative damage. Similarly, to hydroxyurea, the exact mechanism of action of L-glutamine is
unknown. It is thought to act as an antioxidant agent in SCD by preserving NADPH levels
necessary for GSH recycling [41]. The FDA approved oral administration of L-glutamine,
Endari, to treat SCD in 2017 after successful completion of phase 2 and phase 3 clinical trials
[42]. The results from these trials showed a reduction in the frequency of painful crises as well
as a reduction in emergency department visits [43] Currently, Endari is only approved for use in
patients five years of age or older. Unlike hydroxyurea, Endari does not directly target VOs,
instead Endari is used as a preventative treatment to reduce the severity as well as frequency of
VOCs.

1.5.3

Pharmacologic Therapies Under Investigation
Although only two drug therapies have been approved for treatment of SCD, numerous

therapeutic targets are being investigated. The increased understanding of the complexity and
12

multiplicity of the pathophysiology of SCD has led to the new therapeutic strategies. Therapeutic
targets under investigation include but are not limited to agents that augment NO bioavailability
(or its targets), target cellular adhesion, platelet aggregation or coagulation, and inhibit
hemoglobin polymerization [41], [44], [45].

1.5.3.1

Therapeautics that Augment NO Bioavailability or NO Targets
As previously mentioned, the NO-sGC signaling pathway plays a crucial role in the

physiology of the cardiovascular system, specifically in relation to vasodilation. When NO binds
to heme it activates the catalytic domain on sGC which enables the synthesis of of cGMP from
guanosine triphosphate (GTP). Impaired NO signaling and altered NO-cGMP homeostasis are
considered hallmarks of cardiovascular diseases and are thus important therapeutic targets [46].
Multiple therapeutic strategies have been investigated to combat the reduced NO bioavailability
observed in SCD. Preliminary studies of inhaled NO gas demonstrated some therapeutic effects
in patients suffering from acute VOCs [45], [47]–[50]. However, a subsequent larger doubleblind, placebo-controlled study in 150 patients hospitalized with VOC yielded no clinically
significant effects of inhaled NO [45], [46], [51]. L-arginine has been studied as another strategy
to promote NO bioavailability[45], [46], [51]–[54]. Reduced arginine levels are considered a
rate-limiting step for NO production during VOC. Oral administration of L-arginine in
conjunction with HU demonstrated an increase in nitrate levels. Additionally, in a double-blind
placebo-controlled trial on 38 children with SCD, L-arginine administration corresponded with
reduced opioid us and lower pain scores [55].
The sustained mechanisms that constrict NO production and bioavailability are likely
responsible for the limited efficacy of NO inhalation and L-arginine supplementation on NO13

sGC signaling restoration. As an alternative, the molecular target of NO, sGC, has been
investigated [23], [46], [51], [56], [57]. The target of two classes of sGC therapeutics are hemedependent sGC stimulators and heme-independent activators. The sGC stimulators not only
interact with endogenously available NO but are also capable of direct binding and stimulation of
sGC to synthesize cGMP independently of NO. Riociguat and Olinciguat are two such sGC
stimulators currently being investigated [51], [58]. In 2013, Riociguat was approved for the
treatment of of pulmonary hypertension. A phase 2 double-blind, placebo-controlled study
(NCT02633397) is currently being conducted to evaluate the safety, tolerability and efficacy in
patients with SCD. Study completion is estimated in June of 2022. It should be noted, due to the
short half-life of Riociguat thrice-daily dosing is required. In contrast, Olinciguat is a once-daily
dose. In a phase 1b placebo-controlled study, olinciguat increased plasma cGMP levels and no
serious adverse effects were observed [58]. Based upon the study, the FDA granted orphan drug
status as a potential treatment for SCD. A phase 2 placebo-controlled, double-blind study
(NCT03285178) in patients with SCD was completed in the summer of 2020. The results from
this study have not be published yet.

1.5.3.2

Therapeutics That Target Cellular Adhesion
Vascular occlusion is thought to be the cause of the sickle cell pain crises. To combat

vascular obstruction generated by the adhesion of sickled RBCs and white blood cells (WBC) to
the endothelium anti-adhesive agents that target RBC and WBC endothelial interactions are being
investigated [41], [44], [45]. The adhesion process in RBC and WBC is mediated by P- selectin
thus making P-selectin inhibitors potential therapeutics. Crizanlizumab (SEG101) is a humanized
monoclonal antibody that binds to P-selectin and prevents interaction with P-selectin glycoprotein
14

1 [59]. Completion of a 12-month, phase II placebo-controlled, double-blind safety and efficacy
study, reported a 45.3% decrease in the frequency of crises per year [60]. No differences were
observed in hemolytic parameters suggesting that the reduction in crises was due to the modified
cellular adhesion. Based upon the findings of the study, the FDA granted Breakthrough Therapy
designation to crizanlizumab in January of 2019 for the prevention of VOC in individuals with
SCD. Pan-selectin inhibitors are also being investigated as anti-adhesive agents. Rivipansel (GMI1070) is one such agent that inhibits cell-cell interactions and adhesion [41]. A phase 3 study
(NCT02187003) to evaluate the efficacy and safety in patients 6 years of age or older suffering
from a pain crisis related to SCD that requires hospitalization was completed in June of 2019.
Results have yet to be published.

1.5.3.3

Therapeutics that Target Platelet Aggregation or Coagulation
Another avenue of interest includes therapies that target platelet activation and interaction

inflammatory cells. Ticagrelor is a P2Y12 ADP receptor antagonist that has some influence on
the vascular tone and inflammatory response. Ticagrelor is already an approved blood thinner but
is now being investigated as a potential treatment for SCD [61]. A phase 3 clinical trial
(NCT03615924) to investigate the effect of Ticagrelor in reducing the frequency of VOC in
pediatric patients with SCD was terminated early following a recommendation from an
independent data monitoring committee.
1.5.3.4

Therapeutics that inhibit Hemoglobin Polymerization
Example Paragraph Although the polymerization of HbS is considered the root cause of

SCD, all of the previously mentioned therapies are directed towards the downstream
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consequences of HbS polymerization, such as nitric oxide bioavailability, adhesion of RBC, and
coagulation. Less attention has been devoted to the investigation of preventing or limiting
hemoglobin polymerization. Recently, an oral anti-sickling agent, Voxelotor (GBT440),
developed by Global Blood Therapeutics (GBT) has proved promising. Voxelotor prevents red
cell sickling and inhibits the generation of HbS fibers that make red cells less flexible by blocking
HbS intermolecular contacts [62]. In 2018, the FDA granted Breakthrough Therapy Designation
(BTD) to voxelotor for the treatment of SCD and based on the results from a Phase ½ clinical
study (NCT02285088), the FDA granted GBT with a new drug application in September of
2019. The published results demonstrated an increased hemoglobin levels, reduced hemolysis and
hemoglobin aggregates in all patients who were treated for more than 28 days [63]. No severe
adverse side effects were reported. A Phase 3 HOPE , double-blind, placebo-controlled study
(NCT03036813) in SCD patients age 12 and older and a Phase 2A HOPE-KID 1 (NCT02850406)
trial in pediatric patients with SCD aged 4 to 17 are currently ongoing.

1.5.4

Red Cell Transfusions
RBC transfusion therapy is considered a crucial treatment in decreasing morbidity and

mortality in SCD. It is estimated that 90% of adults with SCD will receive at least one RBC
transfusion for the treatment of acute or chronic complications associated with SCD [64]. These
complications include perioperative, silent cerebral infarcts, acute anaemia, ACS, acute pain, and
stroke. Following a RBC transfusion, there is an immediate reduction in the concentration of HbScontaining RBC and a correction of anaemia. The reduction in the concentration of HbScontaining RBC is likely to reduce the tendency for vaso-occlusion and vascular damage and the
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correction of anaemia improves the oxygen carrying capacity which in turn changes the blood
viscosity which can improve (or impair) oxygen delivery to tissues [65].
Unfortunately, RBC transfusions are linked to several adverse side effects and
complications. Iron overload and alloimmunization are the most problematic complications
associated with the transfusion [44], [64]–[68]. To combat iron overload, chelation therapy is
implemented. There is a high rate of alloimmunization in patients with SCD due to alloantibodies
and autoantibodies [67]. These can lead to delays in transfusion as well as increased labor and cost
for RBC cross-matching. Additional complications may arise due to the increase in hematocrit
levels and whole blood viscosity. Induced hyperviscosity from a large transfusion volume can
inhibit oxygen delivery may promote vaso occlusion [69]. Thus, it is imperative to take extra care
and precautions when determining exchange volumes. Furthermore, transfusions are less common
in low income countries due to the cost, limited blood supply, increased risk of contamination,
and infrastructure.

1.5.5
1.5.5.1

Curative Therapies
Stem Cell Transplantation
Ever since the discovery of SCD, researchers have been searching for a cure. In 1984, the

first cure for SCD was accidentally discovered following a bone marrow transplant to treat a
child’s leukemia. Allogeneic hematopoietic stem cell transplants (HSCT) have since been
successful as a curative treatment for SCD in 85-90% of patients [6]. However HSCT has limited
administration due to a limited donor pool, cost, graft failure and the possibility of long-term
adverse effects. Considering the low availability and risk of host rejection leading to morbidities
and mortalities, HSCT is generally reserved only for the most severe cases of SCD, such as those
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undergoing chronic transfusion therapy [6]. Patients with human leukocyte antigen (HLA)matched sibling donors experience a mortality rate of 5% and an event free survival of
approximately 90%. Unfortunately, only 10-20% of patients have an HLA sibling available and
when an alternative donor is used, the mortality rate increases to 10-24% [44]. Furthermore, the
high costs and required infrastructure seriously restrict HSCT treatment in lower income and
developing countries [68], [70], [71].

1.5.5.2

Gene Therapies
Gene therapy is a promising potential treatment to abrogate SCD through the manipulation

of HSC via a number of strategies including viral vector-mediated insertion of a function betaglobin gene, as well as gene-editing techniques with CRISPR/Cas9 that reduce intracellular
sickling and enhance production of HbF [72], [73]. The major advantage of gene therapy over
HSCT is the ability to use the patient's own stem cells thereby negating the need to identify a
donor and eliminating associated complications and risks such as graft-versus-host disease.
However, gene therapy like HSCT does require radiation exposure and chemotherapy. Phase ½
trials are currently underway to determine the efficacy and safety of gene therapy utilizing
lentiviral vectors (NCT02247843, NCT02186418). These trials have estimated completion dates
of August 2022 and June 2035. In addition, there are multiple phase ½ trials are currently
recruiting patients to test the safety and efficacy of genome edited HSC through the use of various
products including GPH101, EDIT-301, OTQ923 and HIX763 (NCT04819841, NCT04853576,
NCT04443907).
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1.6
1.6.1

Project Outline
Research Hypothesis
SCD is an inherited blood disorder that can manifest in a variety of symptoms and

complications. The leading cause of death of individuals suffering with SCD are
cardiopulmonary complications with approximately 30% of SCD deaths related to the heart. A
better understanding of the mechanisms and pathways that contribute to the cardiomyopathies in
SCD has the potential to uncover novel therapeutics to inhibit disease progression. The sickled
vascular microenvironment is characterized as an inflammatory state.
This project proposes the use of an in vitro disease model to investigate the mechanisms
that contribute to SCD-related cardiomyopathies. A pathological state will be induced by
exposing cardiac tissues to ANG II or the sickled microenvironment, specifically, serum
proteins. The sickled vascular microenvironment is characterized as an inflammatory state with
increased ROS, that can lead to ischemia and endothelial dysfunction. The goal of this study is to
recapitulate in vivo features of SCD-cardiomyopathies by investigating the effects of ANG II or
the sickled serums on gene expression, and oxidative stress generation. This work will provide
insight into the mechanisms and pathways that contribute to SCD related cardiomyopathies
which has the potential to identify novel targets for treatments.
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CHAPTER II
INDUCED CARDIAC DYSFUNCTION ON A CHIP
2.1

The Renin-Angiotensin-Aldosterone System and Cardiac Pathology
To create a landscape page, you just rotate the page using the “Orientation” option in the

Layout Tab. This will put your page number at the bottom of the page. If you would like to
print a hard copy and have the page number similar to the portrait pages, we can help you make
those changes. The renin-angiotensin aldosterone system (RAAS) is a hormonal pathway
involved in the homeostatic control of arterial pressure and extracellular volume. As indicated by
the name, the three main components of the system are renin, angiotensin and aldosterone. The
pathway begins with the biosynthesis of renin by juxtaglomerular cells (JGC). The JGC release
mature renin from storage granules by an exocytic process. Since renin regulates the initial ratelimiting step of the RAAS, renin secretion acts as a key determinant of RAAS activity[74].
Renin secretion is regulated through interdependent factors including NaCl delivery to macula
densa cells, negative feedback through direct action of angiotensin II (ANG II) on JGC,
sympathetic nerve stimulation, and a renal baroreceptor mechanism. When renin is secreted, it
acts upon circulating angiotensinogen (AGT) cleaving the 10 amino acids from the N-terminal
to form the biologically inert decapeptide angiotensin I (ANG I) [75], [76]. In the human heart,
chymase is responsible for the majority of ANG II generation from ANG I or the dodecapeptide
ANG (1-12), as opposed to the use of angiotensin converting enzyme (ACE) as observed in the
classical endocrine pathway [77]–[79]. ANG II is the vasoactive octapeptide (Asp-Arg-Val-Tyr20

Ile-His-Pro-Phe) that is considered the primary product of the RAAS, although other metabolites
of ANG I and II may also play a significant role in biological activity [75], [76]. ANG II and the
RAAS are key components in maintaining cardiovascular homeostasis in regard to hypertrophy,
cardiac protection, arrhythmias, contractility, fibrosis and heart failure.
ANG II has two main receptors, the losartan-sensitive receptor termed AT1R and the
losartan-insensitive receptor termed AT2R [80], [81]. Both AT1R and AT2R belong to the
seven-transmembrane G protein-coupled receptor (GPCR) superfamily. The AT1R is expressed
in various tissues including endothelium, heart, vascular smooth muscle, brain, kidney, adipose
tissue, and adrenal gland and plays a central role in the physiological functions induced by ANG
II [82], [83]. In addition, the cardiac pathogenesis, including inflammation, increased oxidative
stress, hypertrophy, proliferation and extracellular matrix remodeling, induced by the molecular
and cellular actions of ANG II are almost exclusively mediated by AT1R signaling mechanisms
[82], [84], [85]. In contrast to AT1R, AT2R stimulation is associated with beneficial effects in
the cardiovascular system through promotion of vasodilation, reduction of fibrosis,
inflammation, and oxidative stress. Therefore, an appropriate balance between AT1R and AT2R
activation and stimulation plays a crucial role in the regulation of physiological functions [86].
Dysregulation of the RAAS plays an integral role in the pathophysiology of
cardiovascular disorders. In vitro and in vivo studies have reported that ANG II induces
pathological conditions including myocardial infarction, hypertrophy, and heart failure [85],
[87]–[93]. In cultured cardiomyocytes, ANG II has been shown to induce a series of changes
indicative of a hypertrophic response including re-expression of fetal cardiac genes like
natriuretic peptides, increase in cell size, and reorganization of contractile proteins [84], [85],
[94]–[96]. Similarly, ANG II has been shown to induce endothelial dysfunction in vitro and in
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vivo as demonstrated by reduced NO bioavailability, an increase in ROS, upregulation of
adhesion molecules, and a proinflammatory state [85], [91], [97]–[100]. Furthermore, mice
infused with ANG II led to cardiac hypertrophy fibrosis, increased blood pressure, and reexpression of fetal genes [85], [101]. To build upon these studies, I will exploit the pathological
effects of ANG II to induce cardiac dysfunction in vitro using engineered neonatal ventricular
mouse cardiomyocytes and mouse cardiac endothelial cells. In vitro disease models provide an
affordable alternative to animal models. The work presented here on in will provide a better
understanding of early stage cardiac dysfunction and disease progression.

2.2
2.2.1

Materials and Methods
Microcontact Printing
Engineered cardiac tissues were developed by seeding cardiac cells onto microcontact

printed templates. The mask was previously constructed at Harvard University by Dr. Horton.
Briefly, the mask was engineered using AutoCad (Autodesk, Inc., San Rafael, CA) to contain
rectangular arrays of 15 µm lines with 2 µm spacings. Silicon wafers with SU-8 2002 photoresist
(MicroChem, Newton, MA) coating were subjected to UV light. Subsequently, the wafers were
exposed to SU-8 developer to expose the mask features. Afterwards, the wafers were subjected
to salinization. Polydimethylsiloxane (PDMS) (Slygard 184, Dow Corning, Midland, MI) was
poured onto the wafer to create stamps. The PDMS covered wafer was then degassed to remove
all air bubbles before curing at 65°C for at least 4 hours. The cured PDMS stamps were carefully
cut and removed from the wafer and cleaned in 70% ethanol. The PDMS stamps containing the
rectangular arrays of 15 µm lines with 2 µm spacings were used to pattern fibronectin onto
PDMS coated coverslips.
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Figure 2.1

Visualization of PDMS Stamps using a light microscope PDMS Stamps with
rectangular arrays of 15 µm lines with 2 µm spacings

This was accomplished by “inking” PDMS stamps was 50 µg/ml fibronectin (BD
Biosciences, Bedford, MA) for 1 hour. The excess fibronectin was removed after 1 hour and the
stamps were left to dry. While the stamps were drying, 15:1 (527:184) PDMS coverslips were
cleaned and treated in a UVO cleaner for 8 minutes. Microcontact printing was then performed by
gently placing the fibronectin coated side of the stamp onto a UVO treated coverslip. To ensure
proper transfer, the stamp was lightly tapped. The stamp was then removed from the coverslip
taking caution to avoid disruption of the pattern transfer onto the coverslip. The coverslips were
then background treated with 2.5 µg/ml fibronectin for 10 minutes and subsequently rinsed three
times with PBS. The coverslips were stored submerged in PBS at 4°C until cell seeding.

2.2.2

Cell Culture
Cell culture reagents were purchased from Cell Biologics (Chicago, IL) unless otherwise

specified. Mouse primary cardiac endothelial cells (MCEC) were cultured in Endothelial Cell
Medium supplemented with 5-10% fetal bovine serum (FBS), 1% antibiotic-antimycotic, 0.1%
epidermal growth factor, 0.1% Heparin, 0.1% hydrocortisone, 0.1% vascular endothelial growth
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factor, 0.1% endothelial cell growth supplement, and 2mM L-Glutamine. Cells were seeded into a
T-25 flask precoated with 0.1% gelatin until confluent. Cell culture was carried out at 37 C in a
humidified atmosphere containing 5% CO2. Once confluent the cells were dissociated using 2ml
of 0.25% trypsin-EDTA solution and passaged into T-75 flask precoated with 0.1% gelatin. The
cell culture media was changed every other day. Once confluent, cells were seeded onto chips at
a density of 300,000 cells/cm2. On the following day, the cell culture media was supplemented
with either 0.25% BSA (Sigma Aldrich, St. Louis, MO) or 2% AA/AS/SS serum rather than FBS
for the remainder of the experiment. For the ANG II experiments, the tissues were exposed to 5
nM, 100 nM or 1

M of ANG II daily. In the serum experiments, the media was changed every

other day.

2.2.3

Cell Harvest
Transgenic sickle cell mice have been utilized to better understand the complex

mechanisms and pathways that are associated with the pathophysiology of SCD. There are two
common mice models for SCD: Berkley and Townes. The Berkley mice model knocks-out genes
for endogenous mouse ɑ and β globins (α-/-, β-/-) with transgenes for the expression of human α,
βs, Aγ, Gγ, and β globins [102]. As a result, Berkley mice express HbS almost exclusively. In
comparison, the Townes mice model knocks-in genes replacing the endogenous mouse ɑ-globin
genes with human α-globin genes and endogenous mouse β globin genes with human Aγ and βs
globin genes [103]. One of the major differences between these mice models pertains to the
transition from fetal hemoglobin (γ-globin) expression to sickle β-globin expression. In the
Berkley mice the transition is complete by 15 days gestation. This leads to increased perinatal
lethality translating into small litter sizes [104]. This constitutes a major limitation when
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employing the Berkley mice model. In contrast, the Townes mice transition is complete at 1
month of age thereby mimicking the timeline found in humans. For these reasons, we chose to
employ the Townes mice model.
All animal procedures and the experimental protocols were approved by the Mississippi
State University Animal Care and Use Committee. All materials were purchased from Thermo
Scientific (Waltham, MA) unless otherwise stated. Breeding pairs were ordered from Jackson
Laboratories (Stock No: 013071, Townes model, hα/hα::, βA/βs, hα/hα::383 γ-βA/-1400 γ-βS).
Mice were bred and phenotyped for control (HbAA), sickle trait (HbAS), and sickle cell anemia
(HbSS) human hemoglobins. A previously published cardiomyocyte harvest protocol was
modified and used for this study[105]–[107]. Briefly, ventricles from two-day-old mice were
harvested, rinsed with Hanks Balanced Salt Solution (Gibco Cat# 14175-079), and enzymatically
digested using trypsin (1mg/ml) for 12 hr at 4°C. Tissues were then mechanically dissociated
three times in collagenase II (1mg/ml, Worthington Biochemical, Lakewood, NJ). To reduce the
fibroblast population, the cell suspension was incubated in T-25 flasks containing M199 media
supplemented with 10% Heat inactivated FBS (Gibco Cat. #16140-071), 2 mM L-glutamine
(Gibco Cat. #25030-081), 0.1 mM nonessential amino acids (Gibco Cat. #11140-050), 10 μM
HEPES (Gibco Cat. #15630-080), 19.4 μM glucose (Sigma Aldrich, St. Louis, MO), 50 U/mL of
penicillin (Sigma Aldrich, Cat. #P-4687), and 1.5 μM B12 (Sigma Aldrich, Cat. #V-2876) for 45
minutes at 37°C. The cell suspension was collected and counted. Cells were then seeded onto
chips at a density of 300,000 cells/cm2. After 24 hours, a dead cell wash-off was performed using
PBS and the media was changed. On the following day, the cell culture media was supplemented
with either 0.25% BSA (Sigma Aldrich, St. Louis, MO) or 2% AA/AS/SS serum rather than FBS
for the remainder of the experiment. For the ANG II experiments the media was changed and the
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tissues were exposed to 5 nM, 100 nM or 1

M of ANG II daily. In the serum experiments, the

media was changed every other day.

2.2.4

Gene Expression
Cell lysates were collected at 24 h, 72 h, and 1 week after initial ANG II or serum dosing.

RNA was extracted using the Zymo Quick-RNA MiniPrep kit (Zymo, Irvine, CA). The Nanodrop
spectrophotometer (Thermo Scientific, Waltham, MA) was used to determine the concentration of
RNA. First strand complementary DNA (cDNA) synthesis was then performed using SuperScript
III (Invitrogen, Carlsbad, CA). Quantitative real-time polymerase chain reaction (qRT-PCR) was
then conducted using the QuantStudio 3 Real-Time PCR System (Thermo Scientific, Waltham,
MA). Each sample was tested in duplicate on each plate for each experiment. Primer information
can be found below in Table 2.1.

Table 2.1

PCR Primer gene list for ANG II and sickled microenvironment studies

Symbol

Name
Ribosoma
l Protein
RPL13a L13a
Glucuronid
Gusb
ase Beta 6
IL6
interleukin

Accession

Forward (5'-3')
ATGACAAGAAAAAGC

Reverse (5'-3')
CTTTTCTGCCTGTTT

BC086896 GGATG
NM_0103 AATGAGCCTTCCTCTG

CCGTA
AACTGGCTATTCAGC

68.1
NM_0311

CTCT
CTACCCCAATTTCCAA

TGTGG
ACCACAGTGAGGAAT

connectiv

68
NM_0102

TGCT
GTAACCGGGGAGGG

GTCCA
TACTTGCCACAAGCTG

e tissue

17

AAATTA

TCCA

growth
natriuretic
peptide
factorB
type

NM_0087

CAGCTCTTGAAGGAC

AGACCCAGGCAGAG

26

CAAGG

TCAGAA

CTGF
NPPB
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Table 2.1 (continued)

Symbol Name
nuclear

Accession

Forward (5'-3')

Reverse (5'-3')

NM_0104

CTGGACGTTATCC

GTCAATCCAATCACCA
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GAAAGTG

AAGC

NM_0104

CCTGCCTAAGGAA

CCCAGACTCTCACAG

93
NM_0325

GACATGA
CCAATGCAGAAGA

CATCT
GGGAGGGCAGGAAT

41

GAAGGAA

AAATAA

receptor
NR4A
ICAM

HAMP

subfamily
intercellula
4, group A,
r adhesion
member
hepcidin 1
molecule 1
antimicrobia
l peptide

2.2.5

Kinetic Oxidative Stress
CellRox Green Reagent (Thermo Fischer Scientific, Waltham, MA) was used to quantify

the formation of reactive oxygen species (ROS) in vitro. The dye is weakly fluorescent while in
a reduced state. Once the dye is oxidized by ROS it binds to DNA and thus primarily localized
in the nucleus and mitochondria. MCEC were seeded at a density of 250,000 cells per ml in a
96- well plate precoated with 15:1 PDMS. For the ANG II experiments, the cells were cultured
in media supplemented with 0.25% BSA. For the serum experiments, the cells were cultured in
media supplemented with 2% FBS until their respective treatment time. The cells were treated
for 1 week, 72 hr, 24 hr and 1 hr with either ANG II (5 nM, 100nM or 1 M) or 2% AA, 2%
AS, or 2% SS serum. After one week, 5 M CellRox Green reagent was added to each sample
incubated for 30 minutes. Cells were then washed three times with 1X PBS. Afterwards, 150 l of
cell media was added to each well. Fluorescent intensity (485/520 nm) was analyzed using
Cytation 5 (BioTek, Winooski, VT) every 10 minutes for two hours at 37 C and 5% CO2.
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2.2.6
2.2.6.1

Data Handling
Data Handling for Oxidative Stress Experiments
Prior to performing statistical analysis on the oxidative stress experiments the raw data

was transformed. All of the replicate wells from each individual plate were first averaged
together. Next, the averaged blank wells were subtracted from the averaged experimental wells on
each plate. Finally, the data was normalized from zero to one on a plate basis. The minimum
value on each individual plate was represented as a zero and the maximum value on each plate
was represented as a one. The transformed data was then statistically analyzed as described
below.

2.2.6.2

Data Handling for Gene Expression Experiments
Prior to performing analysis on the gene expression experiments the raw data was

automatically transformed using the QuantStudio Design and Analysis Software. The cycle
threshold (CT) analysis was performed during the PCR stage as well as the melt curve stage. An
amplification value of less than 0.1 was automatically flagged as no amplification via the
software. Primers that failed to amplify on all plates were excluded from further analysis. The
relative minimum and maximum quantification were determined using a 95% confidence level.
The relative fold change was determined using the ΔΔ Ct method through the QuantStudio
Design and Analysis Software using the specified endogenous control primers RPL13A or
GUSB [108]. For ANG II studies, gene expression was normalized to untreated tissues at the
respective time point. In MCEC serum treated studies, gene expression was normalized to 2% AA
serum treated tissues at the respective time point. In Cardiomyocyte treated studies, gene
expression was normalized to the AA cardiomyocytes treated with 2% AA serum or 0.25% BSA,
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at the respective time point. Then a pivot table was utilized to aggregate the data using the mean
relative quantification (RQ) for each sample and gene. Any inconclusive values were omitted
from the aggregation step. This was then used to generate a heat map using MatPlotLib. If the
RQ was 1 the box was shaded green and if the RQ was below 1 the box was shaded red to
represent upregulation and downregulation, respectively.

2.2.7

Statistical Analysis for Oxidative Stress Experiments
After completion of data transformation, statistical analysis was performed. I had no

reason to believe the relationship was nonlinear and thus a multiple regression model was used to
interpret the results, find trends, and statistical significance. To analyze the data, Python 3 was
employed. Python data analysis library, PANDAS, was used to load and organize the
transformed data. Then python’s statsmodel library was used to perform multiple regression
analysis. The multiple regression analysis was used to determine the strength of the relationship
between concentration, duration, or serum type to the amount of oxidative stress produced. To
quantify the effect of the HbS, the number of S alleles present in the serum was used to
categorize the data as follows: AA=0, AS=1, and SS=2.

2.3
2.3.1

Results
ANG II Oxidative Stress
I found two important trends in the ANG II treatments for the MCEC and CM oxidative

stress analysis. In the MCEC experiments, the concentration of ANG II demonstrated a negative
correlation -4.5*10-5 nM^-1 with a p-value of 0.045. This indicates that less oxidative stress was
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produced with an increased concentrated of ANG II. A visual representation of this analysis
can be seen in the figures below. The duration of the experiment in MCEC had a positive
correlation of 0.003 per hour and a p-value of 0.073. This suggest the longer the experiment
continued the higher the concentration of oxidative stress produced in all wells as represented
by an increased relative fluorescence.
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Figure 2.2

The effect of ANG II exposure on oxidative stress in MCEC

Fluorescence intensity measured in MCEC treated with ANG II in media supplemented with
0.25% BSA. The tissues were exposed to varying concentrations of ANG II. A. The effect of
ANG II after 1 week of exposure. B. The effect of ANG II after 3 days of exposure. C the effect
of ANG II after 1 day of exposure. D. The effect of ANG II after 1 hr of exposure. (Mean +
SEM, N=3 tissues)
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Figure 2.3

The effect of ANG II exposure on the kinetic oxidative stress in MCEC

Fluorescence intensity in MCEC over the course of the 2-hour kinetic read. Tissues were treated
with varying concentrations and durations of of ANG II prior to conducting the kinetic read. No
significant differences or trends in the fluorescence intensity were detected in the kinetic read.
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In the CM oxidative stress analysis, the concentration of ANG II produced a negative
correlation coefficient of -2*10^-4 nM^-1 with a p-value of less than 0.0001. This indicates an
inverse relationship between the concentration of ANG II used and the oxidative stress produced.
In contrast to the MCEC oxidative stress experiments, the duration of the experiment was
negatively correlated with a correlation coefficient of -3.5*10^-5 per hour and a p-value of 0.6. I
then asked whether the CM cell type had an effect on the oxidative stress produced during the
ANG II dosing. I discovered the CM cell type had a positive correlation of 0.037 per number of
S alleles with the SS CM exhibiting the highest oxidative stress with a p-value of less than
1*10^-4.
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Figure 2.4

The effect of ANG II exposure on cardiomyocyte oxidative stress

Fluorescence intensity measured in Townes AA, AS, SS neonatal cardiomyocytes treated with
ANG II in media supplemented with 0.25% BSA. The tissues were exposed to varying
concentrations of ANG II. (Mean + SEM, N=2 tissues)
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Figure 2.5

The effect of ANG II exposure on the kinetic oxidative stress in cardiomyocytes

Fluorescence intensity measurd over a 2-hour kinetic read in Townes AA, AS, SS neonatal
cardiomyocytes after exposure to varying concentrations of ANG II
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2.3.2

Serum Oxidative Stress
I found two important trends in the serum dosing for the MCEC and CM oxidative stress

analysis. In the MCEC experiments, the number of S alleles present in the serum was positively
correlated with a correlation coefficient of 234 per S allele and a p-value of less than .0001.
Similarly, to the ANG II treatments, the duration of the experiment in MCEC had a positive
correlation of 0.1276 per hour with a p-value of 0.04. This suggests the longer the experiment
continued the higher the concentration of oxidative stress produced.
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Figure 2.6

The effect of the sickled microenvironment on MCEC oxidative stress

CellRox fluorescence intensity of MCEC after exposure to 2% serum derived from Townes AA,
AS, SS genotypes. For the serum experiments, the cells were cultured in media supplemented
with 2% FBS until their respective treatment time. (Mean + SEM, N=3 tissues)
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Figure 2.7

The effect of the sickled microenvironment on MCEC kinetic oxidative stress

CellRox fluorescence versus kinetic time in MCEC following exposure to 2% serum derived
from Townes AA, AS, SS genotypes. N=3. For the serum experiments, the cells were cultured in
media supplemented with 2% FBS until their respective treatment time. A. Experimental
exposure for 1 week prior to kinetic plate read. B. Experimental exposure for 3 days prior to
kinetic plate read. C. Experimental Exposure for 1 day prior to kinetic plate read. D.
Experimental exposure for 1 hour prior to kinetic plate read. There was a general trend of
increased fluorescence intensity over the kinetic read.
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In the CM oxidative stress analysis, I observed a similar trend as seen in the MCEC. The
number of S alleles present in the serum was positively correlated with a correlation coefficient
of 32.53 per S allele and a p-value of 0.34. In contrast to the MCEC, the duration of the
experiment produced a negative correlation coefficient of -0.37 per hour with a p-value of 0.26.
Next I asked whether the CM cell type had an effect on the oxidative stress produced during the
serum dosing. The analysis revealed a negative correlation between the amount of oxidative
stress produced and the number of S alleles present with a correlation coefficient of -91 and a pvalue of less than 0.0001.
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Figure 2.8
stress

The effect of the sickled microenvironment on cardiomyocyte oxidative

The fluorescence intensity was measured in Townes neonatal cardiomyocytes, AA, AS, and
SSgenotypes. A. The cardiomyocytes were cultured in media supplemented with 2% serum
derived from Townes AA, AS, or SS genotypes for 1 week. B. The cardiomyocytes were cultured
in media supplemented with 2% serum derived from Townes AA, AS, or SS genotypes for 1 hr
prior. (Mean + SEM, N=2 tissues)
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Figure 2.9

The effect of the sickled microenvironment on cardiomyocytes kinetic oxidative
stress

CellRox fluorescence versus kinetic time measured in Townes neonatal cardiomyocytes, AA,
AS, and SS genotypes. A. AA, AS and SS cardiomyocytes cultured in media supplemented with
2% AA serum. B. AA, AS and SS cardiomyocytes cultured in media supplemented with 2% AS
serum. C. AA, AS and SS cardiomyocytes cultured in media supplemented with 2% SS serum.
There was a general trend of increased fluorescence intensity over the kinetic read.
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2.3.3

Gene Expression
I performed qRT-PCR to examine the gene expression profile of genes known to be

influenced by hypertrophy and/or heart failure. The MatPlotLib was then used to generate a
color-coded mosaic to present a visual representation of relative fold regulation in treated
tissues. In MCEC, the heatmap revealed the greatest differences in gene expression occurred
24 hr after initial 5nM ANG II treatment. The analysis displayed an upregulation of
interleukin (IL)-6, connective tissue growth factor (CTGF), natriuretic peptide B (Nppb),
nuclear receptor transcription factor (NR4A), and intercellular adhesion molecule (ICAM).
These genes have been shown to be upregulated in hypertrophy and heart failure in in vitro
and in vivo studies [85], [90], [96], [109]–[112]. These results indicate that 5nM ANG II
induced a pathological gene expression profile in our cardiac engineered tissues after 24
hours.

42

Figure 2.10

ANG II induces pathological gene expression profile in MCEC

Heatmaps were created from qRT-PCR array relative quantification data over the duration of the
experiment. The quantification was normalized to the control tissues at the respective time point.
RPL13a was used as the housekeeping gene. Gene expression profiles differed the most from the
control after 24 hours of 5nM ANG II exposure. Upregulation is indicated by shades of green and
downregulation is indicated by shades of red.

In ventricular cardiomyocytes, the analysis revealed the greatest differences in gene
expression following 1µM ANG II treatment. The AACM displayed upregulation in IL-6,
CTGF, Nppb, and hepcidin (HAMP). Using the untreated AACM as the control tissues, the
SSCM displayed an upregulation in IL-6 and CTGF after exposure to 1µM ANG II for 1
week. These results indicate that we were able to induce a pathological gene expression
profile in our healthy CM using ANG II.
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Figure 2.11

ANG II induces pathological gene expression profiles in cardiomyocytes

Heatmaps were created from qRT-PCR array relative quantification data over the duration of the
experiment. The quantification was normalized to the AA CM control tissues at the respective
time point. RPL13a was used as the housekeeping gene. Gene expression profiles differed the
most from the control after 1 week of 1µM ANG II exposure. Upregulation is indicated by shades
of green and downregulation is indicated by shades of red.
To examine the direct effects of the sickled microenvironment, specifically serum
proteins, on cardiomyocyte health, I treated MCEC and CM with 2% AA, AS, or SS serum. In
the MCEC, relative fold regulation and fold change was normalized to 2% AA treated tissues at
the respective time point. In the CM, relative fold regulation and fold change was normalized to
AACM treated with 2% AA at the respective time point. In the MCEC, the analysis revealed an
upregulation in IL-6 and NR4A and downregulation in CTGF, Nppb, ICAM, and HAMP, 1 week
after initial 2% SS serum exposure. In the AA CM, the analysis revealed an upregulation in
CTGF and a downregulation in IL-6, Nppb, NR4A, ICAM and HAMP, 1 week after initial 2%
SS serum exposure. For comparison, the SS CM displayed downregulation in IL-6, CTGF,
Nppb, NR4A, ICAM and HAMP, 1 week after initial 2% SS serum exposure.
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Figure 2.12

The effect of the sickled microenvironment on gene expression profiles in MCEC

Heatmaps were created from qRT-PCR array relative quantification data over the duration of the
experiment. The quantification was normalized to the 2% AA control tissues at the respective
time point. RPL13a was used as the housekeeping gene. Upregulation is indicated by shades of
green and downregulation is indicated by shades of red.
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Figure 2.13

The effect of the sickled microenvironment on gene expression profiles in
cardiomyocytes

Heatmaps were created from qRT-PCR array relative quantification data over the duration of the
experiment. The quantification was normalized to the AA cardiomyocytes treated with 2% AA
serum at the respective time point. RPL13a was used as the housekeeping gene. Upregulation is
indicated by shades of green and downregulation is indicated by shades of red.

2.4

Discussion
In this study, I simulated ANG II induced cardiac failure and studied the effects of the

sickle microenvironment on a chip using engineered mouse cardiac tissues. Gene expression
profiles in the ANG II treated tissues indicated a pathological state with upregulation in
biomarkers for inflammation, cell adhesion, wall stress and ECM related genes [85], [90], [109],
[110]. This is consistent with previous in vitro and in vivo studies implicating ANG II as a major
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contributing factor in the pathogenesis of cardiovascular diseases and heart failure. Gene
expression analysis is commonly used to characterize disease states, define early diagnosis and is
utilized to establish potential therapeutic targets. I observed an increase in interleukin (IL)-6,
connective tissue growth factor (CTGF), natriuretic peptide B (Nppb), nuclear receptor
transcription factor (NR4A), and intercellular adhesion molecule (ICAM) gene expression. It has
been previously established that inflammatory cytokines, including IL-6, play crucial roles in
early and late stages of cardiac remodeling and heart failure [110], [113]–[115]. In isolated
cardiomyocytes, IL-6 causes negative inotropic effects. Additionally, endothelium derived IL-6
is believed to be involved in adaptive hypertrophic responses [111]. Furthermore, inhibition of
IL-6 in a mice model lead to a decrease in cardiomyocyte hypertrophy and cardiac fibrosis,
demonstrating the pro-hypertrophic and pro-fibrotic properties of IL-6 [111]. Studies have also
indicated that CTGF plays a role in hypertrophy and cardiac fibrosis [116]–[118]. CTGF is a
secreted protein that plays an essential role in ECM synthesis. It is believed that CTGF signaling
pathway is an important mechanism involved in the development of diastolic heart failure.
Natriuretic peptides are commonly synthesized in the atria and left ventricle in response to
elevated wall stress. As a result, they are commonly used as diagnostic and prognostic markers
for hypertrophy and heart failure [119]. Elevation of NR4A has been observed in ECs as part of
proinflammatory response and in CMs after ischemia/reperfusion injury [120]. Furthermore,
NR4A has been implicated as a critical negative regulator of ANG II induced vascular
remodeling in cardiovascular diseases [121].
All of the aforementioned genes have been correlated with ANG II induced cardiac
hypertrophy, fibrosis and/or heart failure. Interestingly, exposure to the sickled
microenvironment led to a downregulation in the majority of these genes suggesting the
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cardiomyopathy observed in SCD occurs via a different mechanism of action or requires longer
exposure. Additional testing incorporating a larger microarray or prolonged culture would shed
some light on the progression of cardiomyopathy in SCD.
In addition, ANG II has been reported to increase ROS generation, specifically by
stimulating NADPH to produce superoxide and hydrogen peroxide (H2O2) [85], [93]. The
results of the oxidative stress experiments displayed a negative correlation between ANG II
concentration and ROS generation. These results appear to be contradictory to what was
expected; however, previous users have reported that H2O2 quenched CellRox’s fluorescence
[122], [123]. This interaction could explain why a negative correlation between ANG II
concentration and fluorescence intensity was observed. In comparison, when the tissues were
exposed to a sickled microenvironment, specifically serum proteins, an increase in ROS
generation was observed. This is indicative of an inflamed state as is expected in the
pathogenesis of cardiovascular disease [124]. It should be noted that the CellRox reagent only
detects intracellular ROS and does not capture intercellular ROS. Further testing and analysis
are required to quantify the intracellular and intercellular ROS generation.
In vitro disease models using organs-on-chip platforms can serve as diagnostic tools for
therapeutic applications. This study utilized PDMS in conjunction with ECM proteins to employ
a biologically relevant platform. PDMS is commonly used to fabricate in vitro platforms due to
its biocompatibility, gas permeability, and optical clarity. To overcome the hydrophobic nature
of PDMS, surface treatment is required to induce a hydrophilic surface to facilitate cell and
protein adhesion. A fibronectin coating was incorporated because it is a major constituent of
cardiac ECM [125]. The endothelial cell monolayers combined with a protein coating serves as a
model endothelium. The work presented here indicates that I was able to recapitulate
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pathological genetic profiles indicative of cardiac pathophysiology in cardiomyocytes and
endothelial cells. We plan on building upon our results by constructing a co-culture device
consisting of engineered cardiac tissues composed of cardiomyocytes as well as endothelial cells.
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CHAPTER III
CONCLUSION AND FUTURE WORKS
3.1

Conclusion
This study focused on two of the essential cell lines that are responsible for the heart’s

structure and signaling cascades as a preliminary step for the development of a microfluidic
system for examining cardiovascular diseases like SCD. To provide a better understanding of the
complex cell-cell interactions in the development of cardiac dysfunction we needed to first
investigate the individual cell response. I found that ANG II induced gene expression profiles
indicative of cardiac pathophysiology. When the cardiac tissues were exposed to the sickle
microenvironment and increase in oxidative stress was observed. This signifies that a sickle
microenvironment is one of an inflamed state. However, the results of the ANG II oxidative
stress experiments were contradictory to what was expected with a decrease in ROS generation.
This could be attributed to limitations of the reagents used and will require further testing and
analysis to confirm. The genetic profiles observed are similar to reported ANG II effects and are
known biomarkers for hypertrophic cardiomyopathy and heart failure indicating that I was
successful in inducing cardiac dysfunction in vitro. This study provides the preliminary results
necessary for the construction of a microfluidic device to recapitulate the vascular
microenvironment to better characterize and investigate vascular related diseases such as SCD.
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3.2

Future Works
Microfluidic devices are advantageous over traditional cell culture due to their ability to

capture features of the in vivo environment such as, cell composition, mechanical stiffness and
natural geometry. The aforementioned features are crucial factors in blood disorders like SCD.
Mechanotransduction, the chemical signals between cells that regulate cellular behavior,
influences cell survival, proliferation, differentiation, adhesion and metabolism. Research over
the past two decades has demonstrated the strong influence of substrate stiffness on
mechanotransduction. In 1997, Pelham and Wang reported that the stiffness of polyacrylamide
gels could regulate focal adhesion and migration of epithelial cells and fibroblast [126]. In
addition, the substrate stiffness can drive differentiation of stem cells into specific lineages or
maintain pluripotency. In 2006, Engler et al demonstrated that varying the elastic modulus of the
substrate directed mesenchymal stem cell differentiation toward bone, neuron or muscle cell
lineages [127]. Furthermore, cardiomyocyte mechanotransduction is affected in heart disease via
a stiffer environment due to increased cardiomyocyte contractile stress with increased elastic
modulus [128]. A stiffer sample had been shown to inhibit contractility in cardiomyocytes and
abruptly change spread area in fibroblasts and endothelial cells [129], [130]. Therefore, it is of
utmost importance to simulate the in vivo stiffness in the development of a physiologically
relevant model to investigate cellular behavior and is why we use a 15:1 (527:185) PDMS blend
to construct our models.
The natural geometry of a human heart consists of approximately 3,300 capillaries per
mm2 and is vital for nutrient transport and waste elimination [131], [132]. Several methods
have been used to mimic the vascularization including decellularized scaffolds, co-culture
techniques incorporating endothelial cells and cardiomyocytes, and microfabrication
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techniques to design vascular structures [133]–[138]. We are currently investigating methods to
effectively fabricate soft PDMS microfluidic devices with varying geometries.
Multicompartmental microfluidic devices consisting of endothelial cells, cardiomyocytes and
protein coatings will provide an in vitro method to capture the intricate cell-cell, cell-ECM and
cell-integrin interactions that contribute to cardiomyopathies. The ultimate goal of this research
is to develop a multicompartmental microfluidic device to mimic the vasculopathy to improve
our understanding of the pathophysiological mechanisms surrounding SCD and identify novel
mechanisms for therapeutic targets to improve not only life expectancy, but also the quality of
life.
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